




3.6.3 Clinical Pharmacology Group

Publications: 23

Impact Factor: 118.⁵⁸

Q1: 11



Research Activity

Publications

- Acuña-Castroviejo D, Escames G, Figueira JC, de la Oliva P, Borobia AM, Acuña-Fernández C. Clinical trial to test the efficacy of melatonin in COVID-19. *J Pineal Res.* 2020; 69(3): e12683. Editorial Material. IF: 13.007; D1
- Borobia AM, Carcas AJ, Arnalich F, Álvarez-Sala R, Manserrat-Villatoro J, Quintana M, Figueira JC, Santos-Olmo RMT, García-Rodríguez J, Martín-Vega A, Buño A, Ramírez E, Martínez-Ales G, García-Arenzana N, Núñez MC, Martí-de-Gracia M, Ramos FM, Reinoso-Barbero F, Martín-Quirós A, Nunez AR, Mingorance J, Segura CJC, Arribas DP, Cuevas ER, Sánchez CP, Ríos JJ, Hernan MA, Frías J, Arribas JR. A cohort of patients with COVID-19 in a major teaching hospital in Europe. *J Clin Med.* 2020; 9(6): 1733. Article. IF: 4.241; Q1
- Borobia AM, Collado SG, Cardona CC, Pueyo RC, Alonso CF, Torres IP, González MC, Codesido JRC, Betegón MA, Barcela LA, Andicoechea AO, Testa AF, Colina JT, Dorribo AC, Galán CD, Ávila JCM, Lugilde ST, Sansuán AJC. Inhaled methoxyflurane provides greater analgesia and faster onset of action versus standard analgesia in patients with trauma pain: InMEDIATE: A randomized controlled trial in emergency departments. *Ann Emerg Med.* 2020; 75(3): 315-28. Article. IF: 5.721; D1
- Borobia AM, Sansuán AJC. Methoxyflurane may provide faster relief than suboptimal treatment, but not Better. *Ann Emerg Med.* 2020; 75(4): 551-552. Letter. IF: 5.721; D1
- Builes MM, Cuenca MV, Soler JLF, Astigarraga I, Martínez AP, Valero JMV, Tong HY, Quiroga JV, Casanova LF, López AE, Sisinni L, Blanquer M, Aguilar IM, Martínez BG, Borobia AM, Pérez-Martínez A. Study protocol for a phase II, multicentre, prospective, non-randomised clinical trial to assess the safety and efficacy of infusing allogeneic activated and expanded natural killer cells as consolidation therapy for paediatric acute myeloblastic leukaemia. *BMJ Open.* 2020; 10(1): e029642. Article. IF: 2.692; Q2
- Cabañas R, Ramírez E, Sendagorta E, Alamar R, Barranco R, Blanca-López N, Dona I, Fernández J, García-Nunez I, García-Samaniego J, López-Rico R, Marín-Serrano E, Merida C, Moya M, Ortega-Rodríguez NR, Becerra BR, Rojas-Pérez-Ezquerro P, Sánchez-González MJ, Vega-Cabrera C, Vila-Albelda C, Bellon T. Spanish guidelines for diagnosis, management, treatment, and prevention of DRESS syndrome. *J Invest Allergol Clin Immunol.* 2020; 30(4): 229-53. Article. IF: 4.333; Q2
- Dal-Re R, Carcas AJ, Sreeharan N. The need to implement non-industry COVID-19 clinical trials in non-high-income countries. *J Glob Health.* 2020; 10(1): 10351. Editorial Material. IF: 4.413; Q1
- García IG, Carcas AJ, Borobia AM. Strategy to effectively and efficiently implement voriconazole pharmacogenetics in clinical practice. *Pharmacogenomics.* 2020; 21(10): 647-9. Editorial Material. IF: 2.533; Q3
- García IG, Rodríguez-Rubio M, Mariblanca AR, de Soto LM, García LD, Villatoro JM, Parada JQ, Meseguer ES, Rosales MJ, González J, Arribas JR, Carcas AJ, de la Oliva P, Borobia AM. A randomi-



- zed multicenter clinical trial to evaluate the efficacy of melatonin in the prophylaxis of SARS-CoV-2 infection in high-risk contacts [MeCOVID Trial]: A structured summary of a study protocol for a randomised controlled trial. *Trials*. 2020; 21(1): 466. Letter. IF: 2.279; Q4
- González-Ramos J, Lamas C, Bellon T, Ruiz-Bravo E, Ramírez E, Lerma V, Lecumberri B. Oseltamivir-induced toxic epidermal necrolysis in a patient with Cushing's disease. *Indian J Dermatol Venereol Leprol*. 2020; 86(5): 515-8. Article. IF: 2.545; Q3
 - Jara P, Baker A, Baumann U, Borobia AM, Branchereu S, Candusso M, Carcas AJ, Chardot C, Cobas J, D'Antiga L, Ferreras C, Fitzpatrick E, Frauca E, Hernández-Oliveros F, Kalicinski P, Lindemans C, Lopes MF, López-Granados E, de Magnee C, Mota C, Muñoz JM, Ojeda JJ, Pérez-Martínez A, Perilongo G, Rascón J, Sciveres M, Stone R, Tarutis V, Toporski J, Torres JM, Wennberg L. Cross-cutting view of current challenges in paediatric solid organ and haematopoietic stem cell transplantation in Europe: the European Reference Network TransplantChild. *Orphanet J Rare Dis*. 2020; 15(1): 16. Article. IF: 4.123; Q2
 - Maseda R, Martínez-Santamaría L, Sacedón R, Butta N, de Arriba MD, García-Barcenilla S, García M, Illera N, Pérez-Conde I, Carretero M, Jiménez E, Melen G, Borobia AM, Jiménez-Yuste V, Vicente A, del Río M, de Lucas R, Escámez MJ. Beneficial effect of systemic allogeneic adipose derived mesenchymal cells on the clinical, inflammatory and immunologic status of a patient with recessive dystrophic epidermolysis bullosa: A case report. *Front Med*. 2020; 7: 576558. Article. IF: 5.091; Q1
 - Peña MA, Muriel J, Saiz-Rodríguez M, Borobia AM, Abad-Santos F, Frías J, Peiró AM. Effect of cytochrome P450 and ABCB1 polymorphisms on imatinib pharmacokinetics after single-dose administration to healthy Subjects. *Clin Drug Invest*. 2020; 40(7): 617-28. Article. IF: 2.859; Q3
 - Prado-Velasco M, Borobia A, Carcas-Sansuán A. Predictive engines based on pharmacokinetics modelling for tacrolimus personalized dosage in paediatric renal transplant patients. *Sci Rep*. 2020; 10(1): 7542. Article. IF: 4.379; Q1
 - Ramírez E, Urroz M, Rodríguez A, González-Muñoz M, Martín-Vega A, Villán Y, Seco E, Monserrat J, Frías J, Carcas AJ, Borobia AM. Incidence of suspected serious adverse drug reactions in corona virus disease-19 patients detected by a pharmacovigilance program by laboratory signals in a tertiary hospital in Spain: Cautionary data. *Front Pharmacol*. 2020; 11: 602841. Article. IF: 5.81; Q1
 - Ramos-Ramos JC, Lázaro-Perona F, Arribas JR, García-Rodríguez J, Mingorance J, Ruiz-Carrasco G, Borobia AM, Paño-Pardo JR, Herruzo R, Arnalich F. Proof-of-concept trial of the combination of lactitol with *Bifidobacterium bifidum* and *Lactobacillus acidophilus* for the eradication of intestinal OXA-48-producing *Enterobacteriaceae*. *Gut Pathogens*. 2020; 12(1): 15. Article. IF: 4.181; Q2
 - Rey JR, Caro-Codón J, Rosillo SO, Iniesta AM, Castrejón-Castrejón S, Marco-Clement I, Martín-Polo L, Merino-Argos C, Rodríguez-Sotelo L, García-Veas JM, Martínez-Marín LA, Martínez-Cossiani M, Buño A, González-Valle L, Herrero A, López-Sendón JL, Merino JL. Heart failure in COVID-19 patients: prevalence, incidence and prognostic implications. *Eur J Heart Fail*. 2020; 22(12): 2205-15. Article. IF: 15.534; D1
 - Rodríguez-Rubio M, Figueira JC, Acuña-Castroviejo D, Borobia AM, Escames G, de la Oliva P. A phase II, single-center, double-blind, randomized placebo-controlled trial to explore the efficacy and safety of intravenous melatonin in patients with COVID-19 admitted to the intensive care unit [MeCOVID study]: a structured summary of a study protocol for a randomized controlled trial. *Trials*. 2020; 21(1): 699. Letter. IF: 2.279; Q4
 - Saborido CM, Borobia AM, Cobas J, D'Antiga L, Frauca E, Hernández-Oliveros F, Jara P, López-Granados E, Muñoz JM, Nicastro E, Ojeda JJ, Pérez-Martínez A, Torres JM, Carcas A. Effectiveness of immunosuppression minimisation, conversion or withdrawal strategies in paediatric solid organ and haematopoietic stem cell transplantation: a protocol of a systematic review and meta-analysis. *BMJ Open*. 2020; 10(12): e037721. Review. IF: 2.692; Q2
 - Saiz-Rodríguez M, Almenara S, Navares-Gómez M, Ochoa D, Román M, Zubiaur P, Koller D, Santos M, Mejía G, Borobia AM, Rodríguez-Antona C, Abad-Santos F. Effect of the most relevant CYP3A4 and CYP3A5 polymorphisms on the pharmacokinetic parameters of 10 CYP3A substrates. *Biomedicines*. 2020; 8(4): 94. Article. IF: 6.081; Q1
 - Urbán JG, Gurrado K, Rivas PCB, Abou Elrous D, Machain MZ, Gómez MR, Rodríguez JG, Plaza BV, Gregorio LY, Fernández EG, Martín CJ, Oliva MOL, García EG, Sánchez GL, Cornejo GC, Gutiérrez RS, Santovena AZ, Hijosa MM, Cambor CF, del Castillo YM, Sisinni L, Sánchez DB, Pérez-Martínez A, Zapardiel ES, Granados EL, Villatoro JM, Zabala RH, Borobia AM, Frías J, Ramírez E. A case-control study to assess the role of polyomavirus in transplant complications: Where do we stand? *Transpl Infect Dis*. 2020; 22(6): e13432. Article. IF: 2.228; Q4
 - Vilchez-Sánchez F, Loli-Ausejo D, Rodríguez-Mariblanca A, Montserrat-Villatoro J, Ramírez E, Domínguez-Ortega J, González-Muñoz M. Lymphocyte transformation test can be useful for the diagnosis of delayed adverse reactions to sulfonamides. *Allergy*. 2020; 75(12): 3267-72. Letter. IF: 13.146; D1
 - Villatoro JM, García IG, Bueno D, de la Cámara R, Estebánez M, de la Guía AL, Abad-Santos F, Antón C, Mejía G, Otero MJ, García ER, Iniesta JF, Carcas A, Borobia AM. Randomised multicentre clinical trial to evaluate voriconazole pre-emptive genotyping strategy in patients with risk of aspergillosis: vorigenipharm study protocol. *BMJ Open*. 2020; 10(10): e037443. Article. IF: 2.692; Q2

Research projects

Borobia Pérez A. Contrato de intensificación (INT19/00055). ISCIII. 2020-2021.

Management centre: FIBHULP

Borobia Pérez A. Coordinación del ensayo clínico Ensayo multicéntrico, adaptativo, aleatorizado y controlado sobre la segu-

ridad y eficacia de las estrategias anti-trombóticas en adultos hospitalizados con COVID-19. New York University School of Medicine. 2020-Ongoing.

Management centre: FIBHULP

Borobia Pérez A. Corona Accelerated R&D in Europe (H2020-JTI-IMI2-2020-21-single-stage). UE. 2020-2025.

Management centre: FIBHULP

Borobia Pérez A. Ensayo clínico aleatorizado y multicéntrico para evaluar la efectividad y la eficiencia de una estrategia de genotipado anticipado de voriconazol en pacientes con riesgo de aspergilosis (P118/01322). ISCIII. 2019-2021.

Management centre: FIBHULP

Borobia Pérez A. European Regimen Accelerator for Tuberculosis - ERA4TB (H2020-JTI-IMI2-2018-15). UE. 2019-Ongoing.

Management centre: FIBHULP

Borobia Pérez A. Marie Skłodowska-Curie Actions - Individual Fellow (CareInTrials). UE. 2019-2023.

Management centre: FIBHULP

Borobia Pérez A. Puesta en marcha del estudio A randomized, double-blind, placebo-controlled, parallel-group, multicentre study of the efficacy and safety of nicotinamide in patients with Friedreich's ataxia (NICOF). ECRIN European Clinical Research Inf. 2020-Ongoing.

Management centre: FIBHULP

Borobia Pérez A. Puesta en marcha y realización del ensayo clínico. Proyecto Acanto y proyecto Facet. Fundación para la Investigación Biomédica Hospital Universitario de Getafe. 2018-Ongoing.

Management centre: FIBHULP

Borobia Pérez A. Registro de pacientes atendidos en la unidad de farmacogenética



del Hospital La Paz y análisis de la actividad realizada desde su creación. Various financiers. 2017-Ongoing.

Management centre: FIBHULP

Borobia Pérez A. Tareas necesarias para la puesta en marcha y realización del ensayo clínico Treatment of high grade non-muscle invasive urothelial carcinoma of the bladder by standard number and dose of intravesical BCG instillations versus reduced number of intravesical instillations with standard dose of BCG, a european association of urology research foundation randomised phase III clinical trial- NIMBUS. Fundación para la Investigación de la Asociación Europea de Urología. 2017-Ongoing.

Management centre: FIBHULP

Borobia Pérez A. Tareas necesarias para la puesta en marcha y realización del estudio observacional Estudio de evaluación y manejo del dolor agudo en Servicios de Urgencias hospitalarias e intervención educativa: estudio Edurg17. Laboratorio Menarini S. A. 2018-Ongoing.

Management centre: FIBHULP

Carcas Sansuán AJ. Contrato de intensificación (INT19/00082). ISCI. 2020-2021.

Management centre: FIBHULP

Carcas Sansuán AJ. Contrato Río Hortega (CM19/00243). ISCI. 2019-Ongoing.

Management centre: FIBHULP

Carcas Sansuán AJ. Identificación mediante diferentes estrategias ómicas, de biomarcadores que permitan la mejora en la individualización de tacrolimus en pacientes pediátricos con trasplante renal

(PI18/00136). ISCI. 2019-2021.

Management centre: FIBHULP

Frías Iniesta J. Unidad clínica de Investigación y Control de Ensayos Clínicos. CM. 2011-Ongoing.

Management centre: FIBHULP

Cibers and Retics

Frías Iniesta J. Plataforma de Unidades de Investigación Clínica y Ensayos Clínicos (PT17/0017/0013). ISCI. (31/12/2020)

Clinical trials

Borobia Pérez, A. Estudio fase 2a, aleatorizado, doble ciego, controlado con placebo, para evaluar un rango de niveles de dosis e intervalos de vacunación de AD26CCOV1 en adultos sanos de 18 a 55 años inclusive.

Type: EECC, phase II.

HULP code: 5630.

Sponsored's protocol code: VAC-31518COV2002 VAC31518.

Sponsored by: Janssen-Cilag España S.A.
Signed date: 08/07/2020

Borobia Pérez, A. Estudio fase 2A, aleatorizado, doble ciego, controlado con placebo, para evaluar un rango de niveles de dosis e intervalos de vacunación de AD26CCOV1 en adultos sanos de 18 a 55 años inclusive.

Type: EECC, phase II.

HULP code: Anexo 2 5630.

Sponsored's protocol code: VAC-

31518COV2001.

Sponsored by: Janssen-Cilag España S.A.
Signed date: 31/12/2020

Borobia Pérez, A. Estudio fase 2A, aleatorizado, doble ciego, controlado con placebo, para evaluar un rango de niveles de dosis e intervalos de vacunación de AD26CCOV1 en adultos sanos de 18 a 55 años inclusive.

Type: EECC, phase II.

HULP code: Anexo 1 5630.

Sponsored's protocol code: VAC-31518COV2002.

Sponsored by: Janssen-Cilag España S.A.
Signed date: 20/10/2020

Borobia Pérez, A. Prevención de enfermedad por Sars-Cov-2 (covid-19) mediante la profilaxis pre-exposición de emtricitabina / tenofovir disoproxil e hidroxycloquina en personal sanitario: ensayo clínico aleatorizado, controlado con placebo.

Type: EECC, phase III.

HULP code: 5576.

Sponsored's protocol code: PREP COVID-19.

Sponsored by: Ministerio de Sanidad, Consumo y Bienestar Social.

Signed date: 03/09/2020

Borobia Pérez, A. Estudio fase I/IIA, de primera administración en humanos, aleatorizado, con observador ciego para evaluar la seguridad, reactogenicidad e inmunogenicidad de tres dosis diferentes de VAC52416 (EXPEC10V) en adultos de entre 60 y 85 años con un estado de salud estable.

Type: EECC, phase I.

HULP code: 5569.

Sponsored's protocol code: VA-C52416BAC1001.

Sponsored by: Janssen-Cilag España S.A.
Signed date: 17/09/2020

Carcas Sansuán, AJ. Evaluación de la farmacocinética de paracetamol en pacientes pediátricos según su status ponderal evaluado mediante IMC: normopeso, sobrepeso y obesidad.

Type: EECC, phase IV.

HULP code: 5685.

Sponsored's protocol code: PARA-OBES.

Sponsored by: Carcas Sansuán, Antonio J.
Signed date: 24/11/2020

Frías Iniesta, J. Multi-centre, phase 2, open-label, randomized clinical trial to evaluate the inhibition of ovulation of 3 dosing strengths of levonorgestrel (LNG) vaginal delivery system (VDS), releasing during 28 days in continuous regimen, versus desogestrel [Cerazet®].

Type: EECC, phase I.

Sponsored's protocol code: LR-201.

Sponsored by: UAM.

Signed date: 30/11/2020

Frías Iniesta, J. Phase I, multi-centre, open-label clinical trial, to assess the suitability of oral calcifediol [25(OH)D] soft gelatine capsules dosage, in subjects with 25(OH)D deficiency, according to their baseline levels [POSCAL].

Type: EECC, phase I.

Sponsored's protocol code: HIDR-0520/POS.

Sponsored by: UAM.

Signed date: 20/01/2020.





Patents and trademarks

Carcas Sansuán AJ, author; Carcas Sansuán AJ, assignee. Brand name: IBJ IberoAmerican Journals. ESM 3.063.048; 2013 February 12.



Carcas Sansuán AJ, author; Carcas Sansuán AJ, assignee. Brand name: IberoAmerican Journals Plus. ESM 3.063.052; 2013 February 12.



Carcas Sansuán AJ, author; Carcas Sansuán AJ, assignee. Brand name: IberoAmerican Journals Clinical Pharmacology. ESM 3.063.053; 2013 February 12.



Carcas Sansuán AJ, author; Carcas Sansuán AJ, assignee. Brand name: IberoAmerican Journals Medicine. ESM 3.063.049; 2013 February 12.



Lapunzina Badía P, Borobia Pérez AM, Carcas Sansuán AJ, Tenorio Castaño JA, Arias Lajara P, Lubomirov Jristov R, authors; FIBHULP, UAM, assignees. Brand name: PharmArray. USM 86.004.412, CM 11.608.403; 2013 July 08, 2013 February 27.



Herrero Ambrosio A, Ramírez García E, Ojeda Feo JJ, Pérez Rodríguez J, Asensio Martín MJ, González Sánchez ML, Moro Agud M, Lorente Romeo M, López Nieto M, Gómez Rioja R, authors; FIBHULP, assignee. Brand name: SINOIRES. CM 13.080.056; 2014 July 14.



Carcas Sansuán AJ, Borobia Pérez AM, authors; FIBHULP, assignee. Brand name: CRDataX. CM 13.681.614; 2015 May 28.



Lapunzina Badía PD, Borobia Pérez AM, Carcas Sansuán AJ, Tenorio Castaño JA, Arias Lajara P, Frías Iniesta J, Dapia García I, Muñoz M, authors; FIBHULP, UAM, assignees. Brand name: ClinPharmarray. CM15489511; 2016 May 31, 2016 September 07.

